MSMaya Savira

Maya Savira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maya Savira has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The role of synbiotics as adjunctive therapy in prolonging latency period in Preterm Premature Rupture of Membranes

    by Donel S, Amiruddin Hidayatullah, Maya Savira

    HIGHLIGHTS Synbiotics significantly prolonged the latency period in women with preterm premature rupture of membranes (PPROM). The intervention group receiving synbiotics showed a longer latency period (>7 days) compared to the control group (OR = 9.53, p = 0.0126). The study supports the potential use of synbiotics as an adjunctive therapy to improve perinatal outcomes in PPROM cases. ABSTRACT Objective: Preterm Premature Rupture of Membranes (PPROM) is one of the main causes of preterm birth, significantly contributing to perinatal morbidity and mortality. This study aims to evaluate the effect of synbiotic administration on prolonging the latency period in pregnant women with preterm premature rupture of membranes (PPROM). The research explores whether synbiotics, a combination of probiotics and prebiotics, can modulate the inflammatory response and extend the latency period, potentially improving perinatal outcomes in PPROM cases. Materials and Methods: This randomized controlled trial was conducted at Arifin Achmad Hospital and other affiliated hospitals in Pekanbaru, Indonesia. A total of 32 pregnant women diagnosed with preterm premature rupture of membranes (PPROM) were enrolled and randomly assigned into two groups: the control group, which received cefotaxime and placebo, and the intervention group, which received cefotaxime and synbiotics. The primary outcome was the latency period, defined as the time from PPROM to delivery. Data were analyzed using SPSS version 25, with a significance level set at p < 0.05. Results: A total of 32 pregnant women diagnosed with PPROM were enrolled in the study. The control group (n=16) received cefotaxime and placebo, while the intervention group (n=16) received cefotaxime and synbiotics. The latency period was significantly longer in the intervention group (>7 days) compared to that in the control group (OR = 9.53; p = 0.0126). Conclusion: Synbiotics can be an effective adjunct therapy in prolonging the latency period in preterm premature rupture of membranes (PPROM), potentially reducing the risk of preterm birth.

  • Open Access

    Genetic diversity in the E6 and E7 gene of human papillomavirus type 16 among cervical cancer patients in Riau Province, Indonesia

    by Maya Savira, Rachmadina Rachmadina, Azza Enggar Mahargyarani, Muhammad Zhafran Admiral, Donel S, Amru Sofian, Renady Reza Razali, Zidny Ilmiah, Analdi Farniga

    Cervical cancer mostly occurs due to persistent high-risk human papillomavirus (HPV), with type 16 being the most frequent. In Indonesia, cervical cancer ranks second in mortality, with a fatality rate of 57%. The E6 and E7 genes of HPV-16 play crucial roles in the virus’s oncogenic transformation, leading to cervical cancer. This study was conducted to determine the prevalence and genetic diversity of the E6 and E7 genes of HPV-16 in Riau Province, Indonesia. There were 37 HPV-positive samples analyzed using the MY09/11 primers. This was followed by the amplification of the E6 and E7 genes. Nineteen samples were detected as HPV-16, thirteen of which were coinfected with HPV-18. Seven E6 and E7 sequences were aligned compared with the reference sequence NC_001526.4. The most common nucleotide changes in the E6 gene, 7318A>G, was detected in 30.7% of samples, leading to an amino acid change from 65N>S. Three nucleotide changes were identified in the E7 gene of sample 89: two synonymous (7831T>C, 7837T>G) and one non-synonymous (7989A>G), resulting in an amino acid change of 29N>S. The most frequent E7 nucleotide change, 7708G>A, was found in 80% of samples. Phylogenetic analysis revealed that HPV-16 isolates from Riau have close kinship with the European lineage, with 57.1% (E6) and 85.7% (E7). In conclusion, the incidence of cervical cancer in Riau Province caused by HPV-16 is 52.8% and 7318A>G and 7708G>A are the most common genetic diversity. Furthermore, the majority of HPV-16 isolates in Riau Province show close kinship with the European lineage.

  • Open Access

    Genetic variations of the L2 gene in human papillomavirus (HPV) type 16 from cervical cancer patients in Sumatra region, Indonesia

    by Maya Savira, Arnaldi Farniga, Zidny Ilmiah, Rachmadina Rachmadina, Ika A. Rini, Rahmat A. Kemal, Azza E. Mahargyarani, Muhammad Z. Admiral, Amru Sofian, Renardy R. Razali, et al.

    The L2 protein, a minor capsid component of human papillomavirus (HPV), plays a critical role in the HPV life cycle by packaging the viral genome with the L1 protein and facilitating DNA transport to the nucleus. Identifying genetic variations in the L2 gene is essential for improving vaccine development, diagnostic accuracy, and understanding viral evolution, potentially contributing to more effective HPV vaccines. The aim of this study was to investigate the genetic variation of the L2 gene in cervical cancer specimens collected from patients in Riau Province, Indonesia. A single-center, cross-sectional study was conducted at Arifin Achmad General Hospital, Riau Province, involving cervical cancer patients with confirmed HPV16 infection between January 2018 and August 2020. Demographic, clinical, and risk factor data were collected through structured interviews and direct assessments. Cervical biopsy specimens were collected, and viral DNA was extracted for L2 gene amplification using polymerase chain reaction (PCR). Sequencing was conducted on PCR products, followed by single-nucleotide polymorphism (SNP) identification through alignment with the HPV16 reference genome. The amplification and sequencing of the HPV16 L2 gene from 22 cervical cancer specimens revealed 36 SNPs, including 31 nonsynonymous and five synonymous mutations. High-frequency mutations were observed at nucleotide positions 4,074 and 4,177, each detected in 95.45% of the samples. Notable insertions were found at positions 3,668–3,669 and 4,275–4,276, indicating substantial sequence variation. Phylogenetic analysis grouped the sequences into three clusters, with most belonging to sub-lineage A2 (European), while others aligned with A4 (Asian) and East Asian lineages. The observed genetic diversity in the HPV16 L2 gene may reflect regional viral evolution and has potential implications for future vaccine development.


  • Open Access

    BHLHE22 expression as a potential diagnostic and prognostic biomarker in cervical cancer

    by Rachmadina Rachmadina, Darmawi Darmawi, Rahmat A. Kemal, Ina F. Rangkuti, Nurkasanah Siti, Savira Maya

    Background/Aim: Cervical cancer is a prevalent and deadly form of gy-naecological malignancy, particularly among developing countries. BHL-HE22 is a transcription factor that functions as a transcriptional inhibitor and is significant in cancer-related regulatory mechanisms. In cervical can-cer, epigenetic alterations transpire, notably in the BHLHE22 gene, which influences gene and protein expression. The objective of this research was to examine the protein and gene expression of BHLHE22 in tissue from cervix cancer in comparison to those found in normal cervix, to investigate its association with various clinical profiles and prognoses and to assess the association of BHLHE22 gene expression with tumour-infiltrating im-mune cells.Methods: This research employed a cross-sectional analytical study and retrospective cohort analyses. The expression of BHLHE22 protein in tis-sue from cervix cancer and normal cervix was analysed using immunohis-tochemistry (IHC) examinations. The level of BHLHE22 gene expression, clinical profiles and prognosis were collected from the GTEx and TCGA studies. The association of BHLHE22 expression and tumour-infiltrating immune cells has been investigated using the Pearson correlation test or Spearman's rank correlation test from the TIMER database.Results: BHLHE22 protein and mRNA expression in cervical cancer decreased considerably compared to the normal cervix, with protein ex-pression reduced by 1.5-fold and mRNA expression reduced by 3.6-fold, respectively. High levels of BHLHE22 expression were determined to be linked with favourable disease-specific survival. Furthermore, BHLHE22 expression positively correlated with tumour-infiltrating immune cells with antitumour immunity.Conclusion: BHLHE22 expression as a biomarker for early detection a prognostic biomarker for disease-specific survival and a modulator of the immune microenvironment in cervical cancer might be suggested.

  • Open Access

    Promising candidate drug target genes for repurposing in cervical cancer: A bioinformatics-based approach

    by Nurfi Pratiwi, Aida J. Ulfah, Rachmadina Rachmadina, Lalu M. Irham, Arief R. Afief, Wirawan Adikusuma, Darmawi Darmawi, Rahmat A. Kemal, Ina F. Rangkuti, Maya Savira

    Cervical cancer is the fourth most common cancer among women globally, and studies have shown that genetic variants play a significant role in its development. A variety of germline and somatic mutations are associated with cervical cancer. However, genomic data derived from these mutations have not been extensively utilized for the development of repurposed drugs for cervical cancer. The objective of this study was to identify novel potential drugs that could be repurposed for cervical cancer treatment through a bioinformatics approach. A comprehensive genomic and bioinformatics database integration strategy was employed to identify potential drug target genes for cervical cancer. Using the GWAS and PheWAS databases, a total of 232 genes associated with cervical cancer were identified. These pharmacological target genes were further refined by applying a biological threshold of six functional annotations. The drug target genes were then cross-referenced with cancer treatment candidates using the DrugBank database. Among the identified genes, LTA, TNFRSF1A, PRKCZ, PDE4B, and PARP were highlighted as promising targets for repurposed drugs. Notably, these five target genes overlapped with 12 drugs that could potentially be repurposed for cervical cancer treatment. Among these, talazoparib, a potent PARP inhibitor, emerged as a particularly promising candidate. Talazoparib is currently being investigated for safety and tolerability in other cancers but has not yet been studied in the context of cervical cancer. Further clinical trials are necessary to validate this finding and explore its potential as a repurposed drug for cervical cancer.


  • Open Access

    Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial

    by Donel S, Dhini Aiyulie Novri, Yulis Hamidy, Maya Savira

    Background: Preeclampsia is a highly prevalent disease among pregnant women. In the event of hypertensive emergency, nifedipine, labetalol, and hydralazine are assigned as first-line therapies in preeclampsia. Further studies are needed to compare the effectiveness of these drugs to find the most cost-effective drug with minimal side effects. This study aimed to compare the effectiveness of these drugs in lowering blood pressure during hypertensive emergencies in severe preeclampsia. Methods: 60 pregnant women with severe preeclampsia were recruited in this multiple centre double-blind randomized clinical trial from May 2021 to April 2022 in Indonesia. The patients were divided equally into three groups and treated with three doses of nifedipine, labetalol, and hydralazine, respectively within one hour with 20 minutes interval. The effectiveness was measured based on systolic and diastolic blood pressures, and mean arterial pressure (MAP). The observation was carried out until five hours post-third dose administration. Results: The blood pressure was reduced significantly after the administration of the first to the third dose of each antihypertensive (plabetalol>hydralazine (57.49%, 42.13%, and 40.87%, respectively) for single dose and hydralazine>nifedipine>labetalol (111.3%, 85.12%, and 90.04%, respectively) for triple dose. Conclusions: Nifedipine is the most effective drug to reduce the blood pressure when single dose administration is used, but requires more doses to further reduce the blood pressure. Hydralazine is the most effective when the drug administration is maxed up to three doses within 60 minutes with 20 minutes interval. Thai Clinical Trials Registry (TCTR): TCTR20221014007 (14/10/2022)


  • Open Access

    Optimization of multiplex PCR composition to screen for SARS-CoV-2 variants of concern

    by Maya Savira, Enikarmila Asni, Rahmat Azhari Kemal

    Background: The ongoing COVID-19 pandemic has led to the emergence of several variants of concern. To rapidly identify those variants, screening samples for whole-genome sequencing (WGS) prioritization could be performed. Objective: We optimized the polymerase chain reaction (PCR) screening method to identify the mutation in spike and ORF1a regions. Methods: We adopted primers targeting mutation in spike and ORF1a region from another study. We optimized the PCR screening method using kits readily available in Indonesia. Firstly, we compared N1 and N2 primers as internal positive control. We also compared GoTaq® 1-Step RT-qPCR System and Indonesia TFRIC-19 BioCOV-19 for the multiplex reaction. We used the optimized composition to screen SARS-CoV-2 positive samples from April – June 2021. Samples with spike and/or ORF1a target failure were subjected to whole genome sequencing (WGS). Results: The results demonstrated the N2 BioCOV-19 reaction as the optimized multiplex PCR composition for spike and ORF1a mutations screening. Whole-genome sequencing has shown that a sample with spike and ORF1a targets failure to be Alpha variant, while other samples with single target failure as non-variants of concern. Therefore, a multiplex RT-PCR composition has been optimized to detect mutation in spike and ORF1a regions. Conclusion: We have optimized a multiplex RT-PCR composition to detect mutation in spike and ORF1a regions.

  • Open Access

    Prevalensi dan Pola Sensitivitas Antimikroba Multidrug Resistant Pseudomonas aeruginosa di RSUD Arifin Achmad

    by Dewi Anggraini, Utari Gusti Yulindra, Maya Savira, Fauzia Andrini Djojosugito, Nopian Hidayat

    Resistensi antimikrob merupakan salah satu masalah kesehatan masyarakat yang besar yang dihadapi manusia sejak era ditemukan antimikrob. Angka multidrug resistant P. aeruginosa salah satunya semakin meningkat di berbagai belahan dunia yang berdampak pada kesulitan penanganan infeksi oleh bakteri ini. Penelitian deskriptif retrospektif ini bertujuan mengetahui prevalensi MDR P.aeruginosa dan pola sensitivitasnya. Data diambil dari hasil kultur bakteri dan uji resistensi antibiotik dari berbagai spesimen klinis pasien di RSUD Arifin Achmad sepanjang tahun 2015. Uji resistensi dilakukan dengan menggunakan alat Vitek 2 compact. MDR P. aeruginosa didefinisikan sebagai P. aeruginosa yang tidak sensitif terhadap tiga atau lebih golongan antibiotik berikut: meropenem atau imipenem, siprofloksasin, gentamisin atau amikasin, seftazidim atau sefepim, dan piperasilin/tazobaktam. Prevalensi MDR P. aeruginosa adalah 45,5%. Isolat MDR P. aeruginosa serta paling banyak berasal dari instalasi perawatan surgikal dan instalasi perawatan intensif, dan paling banyak berasal dari spesimen pus dan sputum. Sensitivitas P. aeruginosa paling baik dengan amikasin (76,9%), piperasilin/tazobaktam (57,2%), meropenem (57,0%), gentamisin (54,5%), sefepim (53,7%), seftazidim (49,6%), ciprofloksasin (48,8%) dan aztreonam (35,5%). Sensitivitas MDR P.aeruginosa terhadap antibiotik jauh lebih rendah dibanding dengan P. aeruginosa. Penelitian ini menunjukkan angka MDR P. aeruginosa tinggi khususnya di Pekanbaru. Pola sensitifas P. aeruginosa dapat menjadi pedoman dalam memilih antibiotik yang sesuai untuk infeksi karena P. aeruginosa.Kata kunci: Multidrug resistant, Pekanbaru, pseudomonas aeruginosa, sensitivitas antibiotik Prevalence and Antimicrobial Susceptibility Profile of Multidrug Resistant Pseudomonas aeruginosa in Arifin Achmad General HospitalAntimicrobial resistance is one of major public health problems since the era of antimicrobial discovery, inclusing multidrug resistant (MDR) P. aeruginosa. The prevalence of this resistance is increasing in different parts of the world, leading to the difficulties in dealing with this bacteria. The aim of this descriptive retrospective study was to determine the prevalence of MDR P. aeruginosa and its susceptibility profile. Data were collected from the bacteria cultures and antibiotic susceptibility test results from various clinical specimens in Arifin Achmad General Hospital throughout 2015. The test was performed in VITEK 2 Compact. MDR P. aeruginosa is defined as P. aeruginosa which is not sensitive to three or more following antibiotics: meropenem or imipenem, ciprofloxacin, gentamicin or amikacin, ceftazidime or cefepime, and piperacilin/tazobactam. The prevalence of MDR P. aeruginosa was 45.5%. The isolates of MDR P. aeruginosa was mostly derived from pus and sputum specimens from the surgical ward and intensive care unit. . The most sensitive antibiotics was amikacin (76.9%) followed by piperacilin/tazobactam (57.2%), meropenem (57.0%), gentamicin (54.5%), cefepime (53.7%), ceftazidime (49.6%), ciprofloxacin (48.8%), and aztreonam (35.5%). Antibiotic sensitivity in MDR P. aeruginosa was much lower than in P. aeruginosa. This study shows a high prevalence of MDR P. aeruginosa, especially in Pekanbaru. This susceptibility profile can serve as a guideline for the selection of appropriate antibiotics for infections caused by P. aeruginosa.Key words: Antibiotic susceptibility, multidrug resistant, Pekanbaru, pseudomonas aeruginosa


  • Open Access

    Validitas Metode Konvensional Modifikasi Terhadap Metode Konvensional Dan ChromidTM Esbl Untuk Deteksi Bakteri-bakteri Penghasil Extended-spectrum Beta-lactamases

    by Maya Savira

    Extended spectrum beta lactamases (ESBL) enzymes producing microorganisms are a major problem in increasingof betalactamases antibiotics resistance include cephalosporins. These enzymes are produced by gram negativesbacilli especially a variety of Enterobacteriaceae, however the most common ESBL producing microorganisms areKlebsiella spp and Escherichia coli. Detection and identification of gram negatives bacilli producing ESBL arechallenging for clinical microbiology laboratory to determine the best method to get the optimal results. The objectiveof this study was to determine the sensitivity and specificity of conventional method modification using MacConkeyadded with cefpodoxim disc 10 μg, 2 mg/l to conventional method and ChromIDTM ESBL. The method of this studywas an observasional analytical study using cross sectional design on 200 isolates, which were Escherichia coli,Klebsiella spp, Salmonella typhi, Proteus mirabilis, Pseudomonas aeruginosa, Serratia spp, and Enterobacter spp.The sensitivity of conventional method modification was 93,8%, conventional method was 68,8% and ChromIDTMESBL method was 100%. The spesificity of conventional method modification was 98,7%, conventional method was11,2% and ChromIDTM ESBL method was 100%. The sensitivity of conventional method modification was higherthan conventional method and as good as ChromIDTM ESBL for detecting ESBL producing bacterias.